pancrelipase (Axcan Pharma Inc.)

Panzytrat is a pancreatic enzyme replacement therapy (PERT) containing pancrelipase, which is a mixture of porcine-derived digestive enzymes including lipase, amylase, and protease. It is primarily indicated for the treatment of exocrine pancreatic insufficiency (EPI) associated with conditions such as cystic fibrosis, chronic pancreatitis, and pancreatectomy. The enzymes in Panzytrat facilitate the breakdown of dietary fats, proteins, and carbohydrates into absorbable units in the small intestine. The product is typically formulated as enteric-coated microtablets within capsules to protect the enzymes from degradation by gastric acid, ensuring their release in the alkaline environment of the duodenum. Panzytrat has been developed and marketed by companies including Axcan Pharma, Aptalis, and Forest Laboratories (now part of AbbVie).

Brand names

Panzytrat

Other names

pancreatinpancreatic enzymes